Claus Jepsen Takes Helm as Lupin's Global Specialty President

Lupin appoints Claus Jepsen as President of its Global Specialty Business. Previously at Takeda Pharmaceuticals, Jepsen was pivotal in strategizing for rare diseases. CEO Vinita Gupta believes his expertise in specialty strategy and commercial planning will enrich Lupin's specialty brand.

Drug firm Lupin has announced the appointment of Claus Jepsen as the President of its Global Specialty Business. The announcement was made on Monday as part of Lupin's strategic growth in specialized areas.

Jepsen transitions from Takeda Pharmaceuticals, where he played a crucial role in crafting the Global Strategy for rare diseases. His move to Lupin signifies a step forward for the company in enhancing its specialty brand presence.

Lupin CEO Vinita Gupta expressed confidence in Jepsen's capabilities, highlighting his strengths in specialty strategy, commercial planning, and effective portfolio management across significant markets.

(With inputs from agencies.)